Bifidobacterium infantis 35624 (often referred to as B. infantis 35624) is a specific, well-researched strain of probiotic bacteria. This particular strain was originally isolated from the human gastrointestinal mucosa. It is patented and has been the subject of numerous clinical studies. This strain is also known commercially as Bifantis and has recently been reclassified as Bifidobacterium longum 35624, though it is still widely recognized and sold under its original name.
Mechanism of Action in the Gut
Bifidobacterium infantis 35624 operates within the gastrointestinal tract through several distinct biological processes. It functions by adhering to the intestinal lining, establishing a presence in the gut, which helps it compete with harmful microorganisms for resources and attachment sites. This contributes to a balanced gut flora. The strain also plays a role in strengthening the gut barrier, a protective interface that regulates what passes from the intestines into the bloodstream. B. infantis 35624 has been shown to enhance tight junction barrier function, reducing permeability by increasing the expression of proteins like occludin, which are integral to maintaining the integrity of this barrier.
Association with Irritable Bowel Syndrome
Bifidobacterium infantis 35624 has been extensively studied for its potential to help manage symptoms associated with Irritable Bowel Syndrome (IBS). Clinical trials have demonstrated that this specific strain can significantly improve common IBS symptoms, including abdominal pain, bloating, and gas, with effectiveness observed across various IBS subtypes. Randomized, double-blind, placebo-controlled studies support these findings, showing reductions in abdominal pain, bloating, and difficulty passing a bowel movement. The World Gastroenterology Organisation has recognized this strain for having a strong evidence base regarding its efficacy in IBS management. Some studies suggest that a dose of 1 x 10^8 colony-forming units (CFU) may provide substantial benefit for these symptoms.
Influence on the Immune System
The influence of Bifidobacterium infantis 35624 extends beyond direct gut function to modulating the immune system. The gut microbiota plays a substantial role in immune regulation. This particular strain functions as an immunomodulator, meaning it helps regulate the body’s immune responses. B. infantis 35624 has been observed to promote anti-inflammatory signals while simultaneously down-regulating pro-inflammatory ones. For instance, studies indicate that it can reduce levels of pro-inflammatory markers such as C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6) in the plasma. This immunomodulatory activity has been observed in individuals with inflammatory conditions both within and outside the gastrointestinal tract, including ulcerative colitis, chronic fatigue syndrome, and psoriasis, and has also been shown to induce regulatory T cells, which help to contain inflammatory reactions.
Supplementation and Safety
Bifidobacterium infantis 35624 is readily available through commercial probiotic supplements like Align (North America) and Alflorex (Europe and other regions). These formulations typically contain 1 x 10^9 colony-forming units (CFU) of B. infantis 35624 per serving, a dosage that has been shown to be effective in clinical settings. The supplement is generally administered once daily, with or without food, and does not require refrigeration due to its specialized packaging. The safety profile of B. infantis 35624 is considered similar to that of a placebo, indicating a good tolerability. It holds Generally Recognized As Safe (GRAS) status by the FDA, reflecting its established safety for human consumption. While generally well-tolerated, some individuals might experience mild side effects such as initial stomach gas or bloating when first beginning supplementation.